Amanta Healthcare Q2 FY26 PAT up 31% YoY at Rs 282.70 lakh
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q2 and H1 FY26 results for period ended Sept 30, 2025. Q2 revenue Rs 7,088.73 lakh, up 6% YoY. Q2 PAT Rs 282.70 lakh, up 31% YoY. H1 FY26 revenue Rs 13,619.41 lakh vs Rs 13,483.1 lakh YoY. H1 PAT Rs 733.36 lakh vs Rs 471.47 lakh YoY, a 56% jump. Exceptional item of Rs 262.88 lakh booked for listing-related share issue expenses. Price Waterhouse gave an unmodified review opinion.
Strong PAT growth despite modest revenue. Exceptional item is non-cash share listing cost. First results as listed company.